Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects
This trial is active, not recruiting.
|Sponsor||Eisai Co., Ltd.|
|Start date||May 2015|
|End date||September 2016|
|Trial size||1 participant|
|Trial identifier||NCT02427607, E2007-J000-341|
To evaluate the safety and tolerability of perampanel given as an adjunctive therapy in participants with epilepsy. This study will be continued until perampanel is commercially available.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Matsuyama, Japan||not available||no longer recruiting|
|Sapporo, Japan||not available||no longer recruiting|
|Inashiki-gun, Japan||not available||no longer recruiting|
|Uji, Japan||not available||no longer recruiting|
|Sakai, Japan||not available||no longer recruiting|
|Matsue, Japan||not available||no longer recruiting|
|Nerima-Ku, Japan||not available||no longer recruiting|
|Niigata, Japan||not available||no longer recruiting|
|Endpoint classification||safety study|
|Intervention model||single group assignment|
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
time frame: From signing of informed consent until perampanel is commercially available or up to 1.5 years
Male or female participants at least 12 years old.
Inclusion Criteria 1. Participants participating in the designated perampanel study as below, and who in the opinion of the investigator continue to benefit from treatment with perampanel Designated perampanel study: E2007-G000-332 (NCT01393743) (with at least 52 weeks of total exposure to perampanel). 2. Provide written informed consent/assent signed by participant or legal guardian prior to entering the study or undergoing any study procedures. If the written informed consent is provided by the legal guardian because the participant is unable to do so, a written or verbal assent from the participant must also be obtained. 3. Female participants of childbearing potential must agree for the duration of the study and for a period of at least 1 month following the last dose of perampanel to be abstinent or to commit to the consistent and correct use of a medically acceptable method of birth control (eg, a double-barrier method [condom plus spermicide, condom plus diaphragm with spermicide]). Exclusion Criteria 1. Participants residing in countries where perampanel is commercially available with respect to the indication or formulation of the designated perampanel study. 2. Female participants who are nursing, pregnant, or planning to become pregnant.
|Official title||An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects|
Call for more information